Regulatory and Technological Aspects of New Drugs for Old Active Pharmaceutical Ingredients
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".
Deadline for manuscript submissions: closed (31 July 2021) | Viewed by 30427
Special Issue Editors
Interests: regulatory science; health policy; medicinal products; compounding; drug delivery systems
Special Issues, Collections and Topics in MDPI journals
Interests: regulatory science; medicinal products; medicine shortages; compounding; drug delivery systems
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The regulatory framework governing the development, production, and marketing of new medicinal products is continuously evolving as a consequence of scientific and technological progress. Its aim is to ensure citizens’ health by establishing provisions that pharmaceutical stakeholders must follow to assure the quality, efficacy, and safety of the medicines they place on the market.
For new medicinal products containing old drug substances, the technological development and the regulatory pathways differ, based on the intention-to-treat of the drug product, e.g., improvement of the therapeutic value of an existing treatment, drug repositioning, or marketing of a therapeutically equivalent copy. Based on product-specific features, regulatory authorities may allow a simplification in the authorization procedure and/or in the nature and extent of the data to be submitted based on the product’s innovativeness, the context in which it has to be authorized (e.g., orphan drugs), and the availability of information from therapeutically equivalent authorized medicaments. However, numerous regulatory and economic barriers still hinder patient access to pharmacological therapies, especially in cases where medicine production is not economically sustainable. Moreover, several technological gaps hinder the reliability of in vitro/in vivo studies performed during the pharmaceutical development of novel medicinal products and assessment of their biorelevance.
In this light, this Special Issue aims to stimulate discussion around possible solutions for rationalizing the regulatory framework and current technological development for promoting the establishment of more reliable methods to develop and assess the quality, safety, and efficacy of new/innovative medicinal products containing old drug substances.
Prof. Dr. Paola Minghetti
Dr. Umberto Musazzi
Dr. Paolo Rocco
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- biorelevant tests
- biosimilars
- comparability exercises
- compassionate use
- drug repositioning
- economic sustainability
- generics
- hybrid applications
- marketing authorization procedures
- off-label
- orphan drugs
- pharmacovigilance
- real-world clinical data
- shortages
- drug formulation
- technological innovation
- therapeutically equivalent copy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.